Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (3747)	9/19/1999 5:02:00 PM
From: Hank	Read Replies (1) \| Respond to of 10293

"Nobody really cares which specific serotypes of rhinoviruses cause the most colds since they share the same mechanism of entry." That is incorrect. While they do share the same mechanism of entry, the I-CAM binding affinity for each rhinovirus is different. Therefore, some rhinoviruses are more difficult to displace from I-CAM than others. That is the the reason why Viropharm's picornavirus drug, pleconaril, is only effect against roughly half of all rhinovirus serotypes. Pleconaril binds to the pocket on the rhinovirus's protein capsid that, in turn, binds I-CAM. So, the conclusion from this is that it IS important to know what rhinoviruses are treatable with zinc and which are not. Otherwise, any conclusion of statistic significance from these clinical studies is premature.